Community Services Advisory Council

The Community Services Advisory Council is composed of individuals with a variety of experiences with ALS who provide input and perspectives to support ALS Canada in improving the journey of people and families living with ALS in Ontario. The Council serves in an advisory capacity to the Board, making recommendations for client service program delivery, community partnerships and provincial advocacy according to the strategic priorities.


Kim Barry
Director, Community Services, ALS Canada

Lisa Flaifel
Vice President, General Medicine, Bayer

Scientific and Medical Advisory Council

The Scientific and Medical Advisory Council provides strategic advice to the Board and management of ALS Canada to ensure all research activities contribute to the vision of ALS Canada, are aligned with the organization’s strategic priorities, are informed by best practices, and are carried out with integrity. The Council also facilitates collaboration within the Canadian ALS research community and supports the Canadian ALS research community’s involvement in international initiatives.


Christine Vande Velde, PhD
ALS Canada Board Member; Associate Professor, Université de Montréal

Turgay Akay, PhD
Dalhousie University

Vanina Dal Bello-Haas, PhD, PT
McMaster University

François Gros-Louis, PhD
Université Laval

Wendy Johnston, MD
University of Alberta

Hanns Lochmüller, MD, PhD
University of Ottawa

Cali Orsulak, BscPharm, BCPS, CDE
Patient Community Representative

Robin Parks, PhD
University of Ottawa

Gerald Pfeffer, MD, PhD
University of Calgary

Janice Robertson, PhD
University of Toronto

Kerri Schellenberg, MD
University of Saskatchewan

Paula Trefiak
Patient Community Representative


Colleen Doyle – Manager, Research & CALS, ALS Canada

Geneviève Matte – CRCHUM, Université de Montréal, CALS Chair (voting member)

Tammy Moore – CEO, ALS Canada

Patrick Nelson – Chair, ALS Canada Board; Principal, Santis Health; family member of a loved one who had ALS

David Taylor – VP Research, ALS Canada

Advocacy Committee

The Advocacy Committee provides professional and personal insight to the Board of Directors and to Staff to help advance our advocacy program. This includes advising the organization on which ALS advocacy priorities to bring forward to government and how to achieve results most effectively. The committee also ensures that ALS Canada’s advocacy efforts align with our strategic plan and are undertaken with the utmost integrity. Members of this committee have a variety of experiences including people and families affected by the disease, government relations experts, health sector professionals, and leading academic ALS researchers.


Richard Ellis
Executive Coach, global business executive & communications expert

Carmen Cels
Director, People & Culture, Roche Canada; and caregiver to a loved one with to ALS

Mike Cels
Person Living with ALS, Retired from Pharmaceutical Sector

Ryan Clarke (ex-officio)
Partner (Division Lead, Advocacy and PR), CRG Eversana Canada Inc.

Lisa Flaifel
Vice President, General Medicine, Bayer

Dr. Angela Genge, MD, FRCP(C)
Director of the ALS Clinic and the Clinical Research Unit, The Neuro (Montreal Neurological Institute-Hospital)

Sherry MacLauchlan
Government Relations and Public Affairs Professional

Stephanie Mazzei
Consultant related to therapeutics, diagnostics, and digital health in cancer care

Tammy Moore (ex-officio, Staff)
CEO, ALS Canada

Patrick Nelson (ex-officio)
Chair, ALS Canada Board; Principal, Santis Health; family member of a loved one who had ALS

Kris Noakes
Community Advocate, living with ALS

Lauren Poplak (ex-officio, Staff)
Manager, Public Affairs & Communications, ALS Canada

Dr. Karin Schnarr
Director, MBA Programs; Associate Professor, Policy & Law at the Lazaridis School of Business & Economics at Wilfrid Laurier University